Please login to the form below

Not currently logged in
Email:
Password:

treatment

This page shows the latest treatment news and features for those working in and with pharma, biotech and healthcare.

Rigel and Ultragenyx claim approvals for rare drugs

Rigel and Ultragenyx claim approvals for rare drugs

According to the company, Tavalisse targets the underlying autoimmune cause of the disease by impeding platelet destruction, providing “an important new treatment option for adult patients with chronic ITP”. ... Fostamatinib was being developed as a

Latest news

  • BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

    The US regulator has given the green light to PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced renal cell carcinoma (RCC) patients on ... As the first treatment option to increase overall

  • P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

    markets, ”highlighting products for muscle, joint and back pain, colds and headaches, and supporting physical activity and mobility, “many of which are treatment areas not currently addressed in P&G’s

  • Amgen and Novartis migraine drug hits the mark again Amgen and Novartis migraine drug hits the mark again

    treatments. The drug - which is vying to become the first calcitonin gene-related peptide (CGRP) receptor-targeting drug to reach the market for migraine - was more than twice as likely to ... Improvements with Aimovig were also observed for secondary

  • Merck’s Keytruda meets survival challenge in NSCLC Merck’s Keytruda meets survival challenge in NSCLC

    It’s another win for Merck in this treatment space over rival Bristol-Myers Squibb, whose PD-1 inhibitor Opdivo (nivolumab) has struggled to find purchase in first-line NSCLC after ... The new data “has the potential to change the treatment

  • AZ taps Ionis for another drug, this time in NASH AZ taps Ionis for another drug, this time in NASH

    NASH is a hot topic in pharma development at the moment, with bigger companies inking licensing deals for new treatments for the disease almost every week. ... and an untapped pharma market as there are as yet no approved treatments.

More from news
Approximately 7 fully matching, plus 1,191 partially matching documents found.

Latest Intelligence

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    Funding initiatives such as CARB-X, ENABLE and GARD-P have pledged around $600m for pre-clinical to clinical translation of new treatments and diagnostics. ... Microbes will continue to evolve to become resistant to new treatments in time, so our

  • Beyond caring: learning from the unsung advocates in cancer care

    However despite this, carers are an often underappreciated stakeholder in what pharma calls the ‘treatment journey’. ... Furthermore, many of us recognise that there is a degree of inevitable suffering that comes with the pain of a cancer diagnosis

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    A diagnosis at least provides an answer as to why the patient has been suffering, often leading to relief, and offers a focal point for accessing treatments (licensed or in clinical ... diagnosis and increase uptake of innovative treatments.

  • Accelerating diagnosis in rare disease Accelerating diagnosis in rare disease

    A diagnosis at least provides an answer as to why the patient has been suffering, often leading to relief, and offers a focal point for accessing treatments (licensed or in clinical ... diagnosis and increase uptake of innovative treatments.

  • The challenges of making genomics a reality for patients The challenges of making genomics a reality for patients

    Cystic fibrosis is one of the conditions where our understanding of genomics is transforming treatment and care. ... The ability to culture the cells in the lab that the prospective treatment works on has been key for Vertex’s success.

More from intelligence
Approximately 2 fully matching, plus 447 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 205 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 19 fully matching, plus 338 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics